June 2-6, 2023
ABSTRACTS & PRESENTATIONS2023 ASCO Annual Meeting - Poster SessionA prospective, cross-sectional, multicentre study to evaluate the clinical performance of the ColoSTAT in vitro diagnostic for the detection of biomarkers associated with colorectal cancer.
Colorectal cancer (CRC) survival rates could be improved if more cancers were detected early. The ColoSTAT blood test and algorithm combines concentrations of 5 protein biomarkers with age and sex to provide an alternative to current CRC screening methods like the faecal immunochemical test (FIT). We compared the performance of ColoSTAT to colonoscopy in detecting CRC.
Abstract: 3529 | Poster Bd #: 229
ABSTRACTS & PRESENTATIONS2023 ASCO Annual Meeting - Publication OnlyCost-effectiveness of ColoSTAT for primary colorectal cancer screening in the United States.
Colorectal cancer (CRC) screening is at the cornerstone of strategies for reducing the mortality, healthcare and societal cost burden of CRC, the third most common cancer in the United States (US). ColoSTAT immunoassay is a simple, highly accurate, minimally invasive blood-based screening test for CRC that will be launched in the US market. Using a de novo decision analytic model, we compared the health benefits and cost-effectiveness of CRC screening with ColoSTAT with current screening offered by private insurers assuming a 5-yearly colonoscopy (COL) or biennial fecal immunochemical test (FIT) for the US population.
Abstract: e15525
CRC Blood Tests: A Future Without Screening Colonoscopies?, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
